Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Centre for Medicines Discovery (CMD) and CAMS Oxford Institute (COI) at NDM, has recently partnered with Ono Pharmaceutical Co (Ono) to validate and develop novel targets in a bid to discover innovative medicines.

In this partnership, Ono has selected neuroscience as the first research theme, one of four key research focus areas and an area of expertise at the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI), which is embedded in the CMD. ODDI will perform target validation experiments and ligand identification. Ono will then use ODDI's results, including hit compounds, to develop and bring new drug candidates to market.

The ODDI is part of the Centre for Medicines Discovery at the Nuffield Department of Medicine, and focuses on translational research and early drug discovery. It possesses highly original seed projects and drug discovery capabilities, based on its researchers’ expertise in neuropathology and structural biology, methodologies ideally suited to the exploration of difficult drug targets. 

Prof John Davis, Professor of Pharmaceutical Discovery, ARUK Oxford  Drug Discovery Institute, said: ‘We are delighted to be starting this strategic collaboration with Ono Pharmaceutical Co, to validate new therapeutic approaches across a range of different unmet medical needs. Combining innovative academic research together with the development insights and capability of pharmaceutical industry partners is key to unlocking the potential of new research findings’.

John contacted COI Prinicipal Investigator, Dr Adan Pinto-Fernandez, to collaborate on the project due to his experience working with companies on translational studies of the ubiquitin system and using deubiquitylating enzymes as a therapeutic target. Adan said: "We are thrilled about the opportunity to collaborate with esteemed researchers at CMD and ODDI, in conjunction with the pharmaceutical company Ono Therapeutics, to target the ubiquitin system in the central nervous system (CNS). Leveraging our expertise in Translational Ubiquitomics, we aim to elucidate the therapeutic implications of our identified targets".

Similar stories

Sarah Gilbert, COI Principal Investigator, receives Royal Society of Chemistry Honorary Fellowship

Professor Dame Sarah Gilbert honoured for outstanding contributions to global vaccine research and public health impact.

Matthew Bottomley: The Latest Winner in CRUK’s ‘Research is Beautiful’ Campaign

Research is Beautiful campaign continues to inspire with some fantastic images. Congratulations to Dr Matthew Bottomley of the CAMS Oxford Institute, his image shoes a cutaneous squamous cell carcinoma infiltrating into the dermis.

Researchers develop new method to identify fake Covid-19 vaccines

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine vial.

New funding to create a Lymphoid Organoid and Explant Hub received from NC3Rs

Dr Pablo F. Céspedes, CAMS Oxford Institute Career Development Fellow, has received funding from NC3Rs to establish a lymphoid organoid and explant hub at the University of Oxford.

Adán Pinto-Fernández wins a 2024 OCION Pump Prime Award

Career Development Fellow Adán Pinto-Fernández has won the CRUK-Centre for his project titled Targeting ISGylation to Boost Cancer Antigenicity: A Novel Approach for Cancer Immunotherapy

University of Oxford unveils new vaccine development partnership

Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian biotech innovator Univercells.

Similar stories

Sarah Gilbert, COI Principal Investigator, receives Royal Society of Chemistry Honorary Fellowship

Professor Dame Sarah Gilbert honoured for outstanding contributions to global vaccine research and public health impact.

Matthew Bottomley: The Latest Winner in CRUK’s ‘Research is Beautiful’ Campaign

Research is Beautiful campaign continues to inspire with some fantastic images. Congratulations to Dr Matthew Bottomley of the CAMS Oxford Institute, his image shoes a cutaneous squamous cell carcinoma infiltrating into the dermis.

Researchers develop new method to identify fake Covid-19 vaccines

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine vial.

New funding to create a Lymphoid Organoid and Explant Hub received from NC3Rs

Dr Pablo F. Céspedes, CAMS Oxford Institute Career Development Fellow, has received funding from NC3Rs to establish a lymphoid organoid and explant hub at the University of Oxford.

Adán Pinto-Fernández wins a 2024 OCION Pump Prime Award

Career Development Fellow Adán Pinto-Fernández has won the CRUK-Centre for his project titled Targeting ISGylation to Boost Cancer Antigenicity: A Novel Approach for Cancer Immunotherapy

University of Oxford unveils new vaccine development partnership

Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian biotech innovator Univercells.